Table 3 Top reasons for discontinuation during FREEDOM and during the Extension
FREEDOM (Years 1–3) | Extension year 5 (Years 1–5) | |||
|---|---|---|---|---|
Placebo (N = 3906) | Denosumab (N = 3902) | Crossover denosumab (N = 2207)a | Long-term denosumab (N = 2343)a | |
Reasons for discontinuation, n (%) | 700 (18) | 630 (16) | 745 (34) | 801 (34) |
Consent withdrawn | 403 (10) | 344 (9) | 325 (15) | 337 (14) |
Other | 20 (1) | 32 (1) | 170 (8)b | 184 (8)b |
Adverse event | 81 (2) | 93 (2) | 93 (4) | 115 (5) |
Death | 78 (2) | 62 (2) | 64 (3) | 80 (3) |
Lost to follow-up | 57 (1) | 57 (1) | 60 (3) | 46 (2) |